DC8988 |
Imiquimod
Featured
|
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist and is commonly used topically to treat warts on the skin of the genital and anal areas. |
|
DC10027 |
Importazole
Featured
|
Importazole is an inhibitor of importin-β transport receptors. |
|
DC9756 |
IMR-1
Featured
|
IMR-1 Inhibits the Notch Transcriptional Activation Complex to Suppress Tumorigenesis. |
|
DC9785 |
IMR-1A
Featured
|
IMR-1A is the metabolite of IMR-1. IMR-1 is a novel class of Notch inhibitors targeting the transcriptional activation with IC50 of 6 μmol/L. |
|
DC12578 |
IMTPPE
Featured
|
IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells. |
|
DC10730 |
Inarigivir(ORI-9020,SB-9000)
Featured
|
Inarigivir(SB-9000) is a novel dinucleotide, evaluated in transgenic mice expressing hepatitis B virus (HBV), significantly reduced liver HBV DNA。 |
|
DC7015 |
INCB024360 analogue(IDO-IN-1)
Featured
|
INCB024360 is a potent IDO1 inhibitor(IC50=10 nM) with desirable pharmaceutical properties, which is poised to start clinical trials in cancer patients. |
|
DC20176 |
INCB057643
Featured
|
INCB057643 is a BET inhibitor that binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones. |
|
DC26025 |
INCB086550(INCB-086550)
Featured
|
INCB086550 is an orally available, small molecule inhibitor of PD-L1 with potential immune checkpoint inhibitory and antineoplastic activities. In vitro, INCB086550 selectively and potently blocked the PD-L1/PD-1 interaction, induced PD-L1 dimerization and internalization, and induced stimulation-dependent cytokine production in primary human immune cells. In vivo, INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade. Preliminary data from an ongoing phase I study confirmed PD-L1/PD-1 blockade in peripheral blood cells, with increased immune activation and tumor growth control. |
|
DC7167 |
Capmatinib(INCB28060)
Featured
|
INCB28060 is a novel orally active inhibitor (IC50=0.13 nM) of c-MET kinase. |
|
DC7429 |
INCB 8761
Featured
|
INCB8761(PF-4136309) is a potent, Selective, and orally bioavailable CCR2 antagonist. |
|
DC8914 |
Indacaterol
Featured
|
Indacaterol is a potent, orally administered ultra-long-acting β2 adrenergic receptor (ADRB2) agonist, widely recognized for its therapeutic potential in respiratory and cardiovascular conditions. By selectively activating ADRB2, indacaterol not only enhances bronchodilation but also exhibits a unique mechanism of action by inhibiting NF-κB activity in a β-arrestin2-dependent manner. This dual functionality helps mitigate lung inflammation, prevent further pulmonary damage, and improve lung function in patients with chronic obstructive pulmonary disease (COPD). Beyond its respiratory applications, indacaterol has also emerged as a valuable tool in cardiovascular disease research, offering insights into its broader therapeutic effects. Its multifaceted pharmacological profile positions indacaterol as a promising candidate for addressing complex disease mechanisms and advancing treatment strategies in both respiratory and cardiovascular fields. |
|
DC8906 |
Indinavir
Featured
|
Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability. |
|
DC4137 |
Indiplon
Featured
|
Indiplon is a novel sedative-hypnotic recently approved for the treatment of insomnia. |
|
DC8838 |
Indirubin
Featured
|
Indirubin is a potent cyclin-dependent kinases and GSK-3β inhibitor with IC50 of about 5 μM and 0.6 μM. |
|
DC20984 |
Indisulam
Featured
|
Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines. |
|
DCAPI1311 |
Indole-3-carbinol
Featured
|
Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1). |
|
DC20276 |
Indotecan(LMP400)
Featured
|
Indotecan(LMP400) is a novel selective and potent topoisomerase I inhibitor with potential anticancer activitity. |
|
DC10483 |
INF39
Featured
|
INF39 is an irreversible and noncytotoxic NLRP3 inhibitor. |
|
DC21138 |
Inflachromene
Featured
|
Inflachromene (ICM) is a microglial inhibitor with anti-inflammatory effects, directly binds high mobility group protein 1 (HMGB1) and HMGB2 and reduces their cytoplasmic accumulation in microglial cells. |
|
DC9651 |
Ingenol 3-angelate
Featured
|
Ingenol 3-Angelate is a PKC(protein kinase C)activator; anti-cancer drug and an active ingredient in Euphorbia peplus. |
|
DC9646 |
Ingenol
Featured
|
Ingenol is an extremely weak protein kinase C (PKC) activator. |
|
DC22212 |
RNF5 INHIBITOR INH-02
Featured
|
inh-02 (RNF5 inhibitor inh-02) is a novel small molecule inhibitor of E3 ubiquitin ligase RNF5/RMA1. |
|
DC7641 |
INH6
Featured
|
INH6 is a potent Hec1 inhibitor, which specifically disrupts the Hec1/Nek2 interaction and causes chromosome mis-alignment. |
|
DC7487 |
Pyroxamide
Featured
|
Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells. |
|
DC7479 |
Tiplaxtinin(PAI-039)
Featured
|
Inhibitor of plasminogen activator inhibitor-1 (PAI-1) |
|
DC7197 |
ML 161
Featured
|
Inhibitor of protease-activated receptor 1 (PAR1)-mediated platelet activation (IC50 = 0.26 μM for the inhibition of platelet P-selectin expression on human platelets). Thought to act allosterically. Also inhibits thrombin-induced platelet activation. |
|
DC7171 |
INK-128(Sapanisertib)
Featured
|
INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms. |
|
DC10555 |
inS3-54A18
Featured
|
inS3-54A18 is a potent STAT3 inhibitor, with anti-cancer properties. |
|
DC7430 |
Obeticholic acid (INT-747)
Featured
|
INT-747(Obeticholic acid; 6-ECDCA) is a potent and selective FXR agonist(EC50=99 nM) endowed with anticholestatic activity. |
|